Related Experiment Video
Updated: Jun 2, 2026
15:09
The Use of Primary Human Fibroblasts for Monitoring Mitochondrial Phenotypes in the Field of Parkinson's Disease
Published on: October 3, 2012
Priorities in Parkinson's disease research
Wassilios G Meissner1, Mark Frasier, Thomas Gasser
1Service de Neurologie et Centre de référence atrophie multisystématisée, CHU de Bordeaux, Avenue Magellan F-33604 Pessac France. wassilios.meissner@chu-bordeaux.fr
Nature Reviews. Drug Discovery
|May 3, 2011
Summary
Parkinson's disease treatments aim to improve motor and non-motor symptoms. New therapies focus on neuroprotection and disease modification, addressing an urgent clinical need for Parkinson's patients.
Area of Science:
- Neuroscience
- Neurology
- Pharmacology
Background:
- Parkinson's disease (PD) involves the loss of dopaminergic neurons in the substantia nigra pars compacta.
- This neuronal loss causes hallmark motor symptoms like bradykinesia, rigidity, and tremors.
- Current dopamine replacement therapies offer symptomatic relief but do not halt disease progression.
Purpose of the Study:
- To review promising biological targets and therapeutic agents for Parkinson's disease.
- To address the unmet clinical need for neuroprotective and disease-modifying treatments.
- To discuss strategies for improving Parkinson's disease management.
Main Methods:
- Literature review of current research on Parkinson's disease therapeutics.
- Analysis of biological targets and emerging therapeutic agents.
- Discussion of challenges and future directions in clinical research.
Main Results:
- Several promising biological targets and therapeutic agents are under investigation for PD.
- Dopamine replacement strategies improve motor symptoms but not underlying disease progression.
- There is a significant need for treatments offering neuroprotection or disease modification.
Conclusions:
- Advancing Parkinson's disease treatment requires understanding genetic factors and improving preclinical to clinical translation.
- Developing effective neuroprotective and disease-modifying therapies remains a critical goal.
- Enhanced clinical trial design is essential for future therapeutic progress.
Related Concept Videos
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...